Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

Background: Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality currently under development as an alternative to daily oral ART. Objective: The LATTE-2 study (ClinicalTrials.gov identifier NCT02120352) showed that cabotegravir LA + rilpivirine LA maintained virologic suppres...

Full description

Bibliographic Details
Main Authors: Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal, Roger LeBlanc, Hans Jaeger, Viviam Canon, David Dorey, Sandy Griffith, Joseph Mrus, William Spreen, David Margolis
Format: Article
Language:English
Published: Taylor & Francis Group 2019-09-01
Series:HIV Research & Clinical Practice
Subjects:
hiv
antiretroviral agent
injectable therapy
long-acting
patient-reported outcome
treatment satisfaction
Online Access:http://dx.doi.org/10.1080/25787489.2019.1661696

Internet

http://dx.doi.org/10.1080/25787489.2019.1661696

Similar Items